| |
|
|
|
3rd Annual Biological Production Forum, The Sheraton, Edinburgh, UK
15th & 16th April, 2004
Thursday 15th April 2004
08:30 Delegate Registration & Coffee
09:00 Chairman’s Introduction
09:10 Opening Keynote Address
09:50 Speeding Biopharmaceuticals Products To Market
10:30 Morning Coffee
11:00 Maintaining A Culture Of Compliance
Stream 1: Design & Build Of A Biopharmaceuticals Manufacturing Site
Stream 2: Outsourcing Manufacturing
13:45 Speed Dating For Business
16:40 Risk Based Gmp’s : Preparing Your Organisation For The Changes
17:05 The Cber/Cder Consolidation Of Products
17:45 Networking Drinks Reception Friday 16th April 2004
09:00 Chairman’s Introduction
09:05 How Many Technology Transfer Runs Do You Need?
09:45 Bringing A Large Scale Biotech Facility Online
10:25 Morning Coffee
Stream 1: Transgenics & Expression Systems
Stream 2: Increasing Operational Efficiency
11:55 Recent Developments And Current Issues In Fermentation
13:45 Innovations In Disposable Technology For Biomanufacturing
14:20 Pdna Manufacture: From Research To Manufacture
Stream 1: Current Commercial Issues In Biopharmaceuticals
Stream 2: Overcoming Technical Issues
16:15 Chairman’s Closing Remarks And Close Of Conference
|
|
|
|
|
|
|
|
Organized by:
|
|
Access Events International Ltd |
|
|
Invited Speakers:
|
|
Dr Dhiren Shah, Aventis Pharmaceuticals, Director, Regulatory CMC, USA
Mr Paul Heiden, Bayer Corporation, SVP, Site Head, USA
Dr David Broad, Biogen Idec Inc, Vice President, Biological Bulk Manufacturing, USA
Dr Andreas Werner, Boehringer-Ingelheim GmbH, Biopharmaceutical Production Management, Germany
Dr Bill Henry, Celltech, Director, Global Technical & Supply Operations, United Kingdom
Dr Wilson Burgess, Clearant Inc., SVP, R&D, USA
Mr Gordon Sherriff, Excell Biotech Ltd, Operations Director, United Kingdom
Mr Mark Elengold, Food & Drug Administration, Deputy Director, Operations, USA
Dr Blair Okita, Genzyme, Senior Vice President, Therapeutics Manufacturing & Development, USA
Dr Sabrina Wagner, Greenovation Biotech GmbH, Chief Executive Officer, Germany
Dr Andrew Racher, Lonza Biologics, Principal Scientist, Cell Culture Process Development, United Kingdom
Mr Frans Hoeks, Lonza Biotec, Director - Biopharmaceuticals Manufacturing, Switzerland
Dr Leopold Bertea, Novartis Pharma SAS, Head, Protein Processing, Biotech Operations Huningue, France
Mr Brian Kerr, Scottish Equity Partners Ltd, Director, Healthcare & Life Sciences Group, United Kingdom
Dr Bernd Krueger, Sigma-Aldrich Fine Chemicals, European Biopharmaceuticals Manager, Germany
Ms Miriam Monge, STEDIM S. A., European Product Marketing Manager, France
Prof Mike Hoare, University College London, Head of Department, Advanced Centre for Biochemical Engineering, United Kingdom
Dr Bob Adamson, Wyeth BioPharma, Vice President, BioPharma Development Network, United Kingdom
|
|
|
|
|
|
|
|
Deadline for Abstracts:
|
|
-
|
|
|
|
|
|
|
|
Registration:
|
|
Contact: Paul Gilbertson, Project Coordinator
paul.gilbertson@access-events.com
Tel: 0044 (0) 20 7940 7070
Fax: 0044 (0) 20 7940 7071
|
|
|
E-mail:
|
|
paul.gilbertson@access-events.com
|
|
|
|
|
|
|
|
|